SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.19-4.7%Jan 15 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: quidditch who wrote (10340)2/8/2004 8:30:29 PM
From: A.J. Mullen  Read Replies (2) of 52153
 
Incyte Press Release: 1.67 -1.77 log10 copies/ml is equivalent to a 50-60 fold reduction. Does that mean much in the case of HIV? I would think not. Surely it will impose a selection process on a notoriously variable and adaptable virus? The survivors will be able to reproduce as effectively as before and hence they will come to dominate, the overall growth rate of the virus will soon resume and te patient will get little respite. But, I'm no immunologist.

I've been unwinding a position in Incyte over the last week or two. I had been waiting patiently for some announcement of some progress. Patience became more difficult as the price improved - apparently without reason. Maybe this press release will allow me to exit completely, but knowing Peter is holding on to his position gives me mixed feelings.

Ashley
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News